Colchicine is an orally active natural alkaloid that acts by inhibiting microtubule polymerization (IC50 = 3 nM) and as a competitive antagonist of the α3 glycine receptor. It possesses broad anti-inflammatory, immunosuppressive, and antifibrotic activities, can inhibit NLRP3 inflammasome activation to prevent NSAID-induced small intestine injury, holds potential for gouty arthritis and rheumatoid arthritis research, and is commonly used to establish Alzheimer’s disease models.

Microtubule:3 nM, A10 cells:0.03 μM (EC50), 786-O cells:0.022 μM

METHODS: Human pharyngeal carcinoma cells FaDu and SNU1041 were treated with Colchicine (0.0-1 μM) for 24-72 h. Cell viability was measured by XTT assay.
RESULTS: Colchicine treatment was cytotoxic to both FaDu and SNU1041 cell lines in a dose- and time-dependent manner. [1]
METHODS: Chorionic villous cells AFCs and amniotic fluid cells CVCs were treated with Colchicine (0.15 μg/mL) for 3-24 h. Apoptosis was detected by Flow Cytometry.
RESULTS: Colchicine induced a significant increase in the proportion of annexin V and PI double positive cells. [2]

METHODS: To investigate the antitumor activity, Colchicine (0.1 mg/kg) was orally administered to BALB/c-nu mice bearing the human pharyngeal cancer tumor FaDu every two days for fourteen days.
RESULTS: Colchicine was effective in inhibiting tumor growth in a hypopharyngeal cancer model nude mouse without serious complications. [1]
METHODS: To investigate the effect of anti-Fas antibody-induced lethality, Colchicine (2 mg/kg) was injected intraperitoneally into C57BL/6 mice, followed by Jo2 antibody (10 μg) 24 h later.
RESULTS: All mice treated with Colchicine survived the lethal attack.Colchicine reduced the susceptibility of mice to the lethal effect of Jo2 against Fas antibody. [3]

a C57BL/6 background are used. To examine the effects of Colchicine on NSAID-induced small intestinal injury, vehicle or Colchicine (1 or 3 mg/kg) is administered orally 30 min prior to indomethacin administration. Mice received intraperitoneal injections of sterilized phosphate buffered saline or mouse recombinant IL-1β (0.1 μg/kg) 3 h after indomethacin treatment. Vehicle or Colchicine (1 or 3 mg/kg) is also administered to NLRP3?/? mice before indomethacin administration. The lesion index is evaluated 24 h after indomethacin administration and examined mRNA and protein expression of inflammasome components 6 h after indomethacin administration.

DMSO: 257.5 mg/mL (644.65 mM), Sonication is recommended.

H2O: 1.33 mg/mL (3.33 mM), Sonication is recommended.